DAX ®13.166,58+0,86%TecDAX ®3.054,96+0,59%Dow Jones28.015,06+1,22%NASDAQ 1008.397,37+1,07%
finanztreff.de

PRESS RELEASE: MorphoSys Continues to Build Commercial Presence by Opening new U.S. Headoffice

| Quelle: Dow Jones Newsw... | Lesedauer etwa 5 min. | Text vorlesen Stop Pause Fortsetzen


DGAP-News: MorphoSys AG / Key word(s): Miscellaneous
MorphoSys Continues to Build Commercial Presence by Opening new U.S.
Headoffice (news with additional features)
2019-11-15 / 17:52
The issuer is solely responsible for the content of this announcement.

Planegg/Munich, Germany, and Boston Massachussetts, November 15, 2019

*MorphoSys Continues to Build Commercial Presence by **Opening new U.S.
Headoffice*

MorphoSys (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR)
announced today the opening of its new U.S. headoffice. Based in Boston, MA,
one of the world's leading innovation and biotech hubs, the new location
will enable MorphoSys to establish and expand its U.S. presence in advance
of the potential commercialization of it first wholly-owned drug candidate,
tafasitamab.

Robert Coughlin, CEO of the Massachusetts Biotechnology Council (Mass BIO),
members from the Boston Mayor's Office, and members from the Massachusetts
Life Science Center (MLSC) attended today's reception and ribbon cutting
ceremony to inaugurate the new U.S. headquarter, located at 470 Atlantic
Avenue, at the Boston habor waterfront.

"As we continue our transformation from a technology provider to a fully
integrated biopharmaceutical company, expanding our presence in the U.S.
further advances our commercialization build-up as we seek FDA approval and
work towards a U.S. launch of tafasitamab by mid-2020," says Dr. Jean-Paul
Kress, Chief Executive Officer of MorphoSys. "The opening of our Boston
headoffice provides the basis for us to achieve our long-term U.S. goals.
I'd like to thank our distinguished guests for celebrating with us today."

"We chose Boston for our U.S. office for its long history of incubating and
encouraging biotech innovation," comments David Trexler, MorphoSys Head of
U.S. Operations. "The location clearly represents our culture of quality and
empowering each other."

About MorphoSys
MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company
dedicated to the discovery, development and commercialization of
exceptional, innovative therapies for patients suffering from serious
diseases. The focus is on cancer. Based on its leading expertise in
antibody, protein and peptide technologies, MorphoSys, together with its
partners, has developed and contributed to the development of more than 100
product candidates, of which 28 are currently in clinical development. In
2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis,
became the first drug based on MorphoSys's antibody technology to receive
regulatory approval. The Company's most advanced proprietary product
candidate, tafasitamab (MOR208), has been granted U.S. FDA breakthrough
therapy designation for the treatment of patients with relapsed/refractory
diffuse large B-cell lymphoma (DLBCL). With global headquarters near Munich,
Germany, the MorphoSys group, including the fully owned U.S. subsidiary
MorphoSys US Inc., has approximately 405 employees. More information at
https://www.morphosys.com [1].

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R),
arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio
Pharma(R), LanthioPep(R) and ENFORCERTM are trademarks of the MorphoSys
Group. Tremfya(R) is a trademark of Janssen Biotech, Inc.

_MorphoSys forward looking statements_
This communication contains certain forward-looking statements concerning
the MorphoSys group of companies, including the expectations regarding the
development of the companys presence in the U.S. The forward-looking
statements contained herein represent the judgment of MorphoSys as of the
date of this release and involve known and unknown risks and uncertainties,
which might cause the actual results, financial condition and liquidity,
performance or achievements of MorphoSys, or industry results, to be
materially different from any historic or future results, financial
conditions and liquidity, performance or achievements expressed or implied
by such forward-looking statements. In addition, even if MorphoSys' results,
performance, financial condition and liquidity, and the development of the
industry in which it operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future
periods. Among the factors that may result in differences are MorphoSys'
expectations regarding the expectations regarding the development of the
companys presence in the U.S., MorphoSys' reliance on collaborations with
third parties, estimating the commercial potential of its development
programs and other risks indicated in the risk factors included in
MorphoSys's Annual Report on Form 20-F and other filings with the US
Securities and Exchange Commission. Given these uncertainties, the reader is
advised not to place any undue reliance on such forward-looking statements.
These forward-looking statements speak only as of the date of publication of
this document. MorphoSys expressly disclaims any obligation to update any
such forward-looking statements in this document to reflect any change in
its expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based or that may affect the
likelihood that actual results will differ from those set forth in the
forward-looking statements, unless specifically required by law or
regulation.

*For more information, please contact:*

*MorphoSys A**G*

Dr. Sarah Fakih
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-26663
Sarah.Fakih@morphosys.com
Dr. Julia Neugebauer
Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-179
Julia.Neugebauer@morphosys.com
Dr. Verena Kupas
Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-26814
Verena.Kupas@morphosys.com

Additional features:

Picture: http://newsfeed2.eqs.com/morphosys/914653.html [2]
Subtitle: MorphoSys: Boston Office Ribbon Cutting Ceremony

Document: http://n.eqs.com/c/fncls.ssp?u=AEIHORBKLG [3]
Document title: Media Release

2019-11-15 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: MorphoSys AG
Semmelweisstr. 7
82152 Planegg
Germany
Phone: +49 (0)89 899 27-0
Fax: +49 (0)89 899 27-222
E-mail: investors@morphosys.com
Internet: www.morphosys.com
ISIN: DE0006632003
WKN: 663200
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID: 914653

End of News DGAP News Service

914653 2019-11-15


1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=3e1886fbba4d35045db9993a27da4719&application_id=914653&site_id=vwd&application_name=news
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=3450dd89575581b5ac06d4bc383130d7&application_id=914653&site_id=vwd&application_name=news
3: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=82eee6ec38a01e3d0af723d4b738bf6b&application_id=914653&site_id=vwd&application_name=news


(END) Dow Jones Newswires

November 15, 2019 11:52 ET ( 16:52 GMT)
Werbung

Das könnte Sie auch interessieren

News-Suche

Suchbegriff:
Werbung

Werbung
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Wie, glauben Sie, wird der DAX am Ende dieser Woche - KW 50 - stehen?
Jetzt abstimmen!
Alle Umfragen ansehen